Canget BioTekpharma (United States)

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Fengzhi Li, Tao Jiang, Qingyong Li et al. · PubMed · 2017 · 225 citations · Full text

Cpt Derivatives, Tumor Biology, Medicinal Chemistry +14

An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

Xiang Ling, Wenjie Wu, Chuandong Fan et al. · Journal of Experimental & Clinical Cancer Research · 2018 · 65 citations · Full text

FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.

Xiang Ling, Xiaojun Liu, Kai Zhong et al. · PubMed · 2015 · 40 citations · Full text

Tumor Biology, Novel Camptothecin Analogue, Oncology +14

FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy

Xiang Ling, Wenjie Wu, Ieman Aljahdali et al. · Clinical and Translational Medicine · 2022 · 35 citations · Full text

Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer

Sreevidya Santha, Xiang Ling, Ieman Aljahdali et al. · Cancers · 2020 · 21 citations · Full text

Human Bladder Cancer, Apoptosis, Cell Death +17